The Supreme Court Just Hit Pause on a Nationwide Ban of Abortion Pills. The Real Decision Comes May 11.
The big picture: On Friday, a federal appeals court banned mail orders of mifepristone nationwide, what the AP called the biggest jolt to abortion policy since Roe was overturned. This morning, Justice Samuel Alito temporarily paused that ruling, restoring access while the Court considers emergency appeals from the drug’s manufacturers. The reprieve lasts about a week. By May 11, the Supreme Court will decide the future of the most common method of abortion in America.
Why it matters: This isn’t just an abortion case. The legal question underneath it is whether a single state’s lawsuit can override the FDA’s authority over a drug it has regulated for more than two decades. If the answer is yes, the same logic applies to vaccines, emergency contraception, gender-affirming care, and any medication a state attorney general decides to challenge.
How we got here
The case started in Louisiana, which sued the FDA arguing that letting people receive mifepristone by mail violates the state’s near-total abortion ban. On Friday, a federal appeals court agreed and blocked mail orders nationwide. The ruling claimed “every abortion facilitated by FDA’s action cancels Louisiana’s ban on medical abortions.”
There’s very little precedent for a federal court overriding the FDA on a drug it has regulated for decades. This wasn’t just an abortion ruling. It was a court telling the FDA it doesn’t get the final word on a drug it approved.
Alito hits pause
The drug’s manufacturers ran straight to the Supreme Court. Danco Laboratories argued the ruling “injects immediate confusion and upheaval into highly time-sensitive medical decisions.” GenBioPro called it “an unfounded and baseless attack on an essential medication.”
This morning, Justice Alito temporarily paused the lower court’s ruling. BUT this is not Alito having a change of heart. He put the ruling on hold until May 11 to give the Court time to weigh the emergency appeals, with all parties ordered to file responses by Thursday. It’s a procedural breath, not a verdict.
Planned Parenthood president Alexis McGill Johnson backed the pause but pointed at the bigger issue, saying “the whiplash and chaos that patients and providers are navigating have already had consequences for people’s lives and futures.”
The bigger target
Mifepristone has been under sustained assault from courts and lawmakers for years. In March, Senator Josh Hawley introduced legislation to effectively ban the abortion pill, framing it as a safety issue. Reproductive health experts pushed back hard. The drug is approved in nearly 100 countries, has been studied for four decades, and the FDA’s review record on it is one of the most extensive for any drug currently on the market.
Taken with a second drug, misoprostol, the regimen is roughly 93 to 99 percent effective. That two-drug protocol is now the most common method of abortion in the U.S., which is exactly why it’s the target. You don’t need to ban abortion outright if you can squeeze the dominant tool.
Why mail orders matter
A study earlier this year found more than 1.1 million abortions in the U.S. in 2025, basically unchanged from 2024 and the highest number since 2009. The number didn’t drop after Roe fell. It held.
The reason it held is what’s in front of the Court right now. Out-of-state travel from people in abortion-ban states actually went DOWN between 2024 and 2025. Telehealth prescriptions into those states went UP. The mechanism doing that work is shield laws, passed in blue states to protect doctors who prescribe these pills across state lines. The Guttmacher Institute put it plainly: telehealth across state lines has become a critical part of access in a country where many states have total bans.
So “mail-order abortion pills” is shorthand for the entire post-Roe access infrastructure. That’s the system the Court will weigh in on by May 11.
What you can do
If you or someone you know needs care during this period of legal uncertainty, Plan C (plancpills.org) tracks current access state by state and lists verified telehealth providers. The Repro Legal Helpline at 1-844-868-2812 handles legal questions confidentially. The National Abortion Federation hotline is 1-800-772-9100 for confidential support and referrals.
By the numbers
May 11 - the Supreme Court’s deadline to rule
1.1 million - U.S. abortions in 2025, the highest since 2009
~100 - countries where mifepristone is approved
93 to 99 percent - efficacy of the two-drug regimen
4 decades - of mifepristone studies on file with the FDA
2020 - when the FDA first allowed telehealth prescription during COVID
The bottom line
We’re a week from a decision that could redraw abortion access in America for the second time in four years. BUT the regulatory question underneath this case may be bigger than abortion itself. If one state can override the FDA on mifepristone, the legal logic doesn’t stop there. Whatever your view, this ruling will affect millions of people, and knowing where the case actually stands is worth more than whatever your feed is screaming about it.
Thanks for reading! Comment your thoughts & reactions | Share to spread the word | Follow to stay in the loop